Who doesn’t love a good news story to kick off the year? ACTA welcomes the recent annoucement that two of its member networks, Australian and New Zealand Children’s Haematology Oncology Group (ANZCHOG) and Cooperative Trials Group for Neuro-Oncology (COGNO) were each awarded $2.5 million as a key initiative of the Australian Brain Cancer Mission to improve access, and raise participation in, local and international trials.
This funding will enable ANZCHOG to open five high quality, international brain cancer clinical trials, with a target of 90 per cent of eligible children with brain cancer enrolling in these trials.
COGNO will begin the start-up of international trials in Australia and increase recruitment by up to 25 per cent in these trials for adults with brain cancer.
The Australian Brain Cancer Mission – coordinated by Cancer Australia – aims to double survival rates and improve the quality of life of people living with brain cancer over the next 10 years, with the longer term aim of defeating brain cancer. The Mission is a partnership between the Australian Government, philanthropists, researchers and clinicians, patients and their families.
ACTA warmly congratulates ANZCHOG and COGNO on this wonderful and important success!
View the media release in full here.